Style | Citing Format |
---|---|
MLA | Asiyabi S, et al.. "Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group." International Journal of Hematology-Oncology and Stem Cell Research, vol. 15, no. 3, 2021, pp. 192-198. |
APA | Asiyabi S, Marashi SM, Vahabpour R, Nejati A, Azizisaraji A, Mustafa AS, Baghernejad A, Shoja Z, Mansouritorghabeh H (2021). Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group. International Journal of Hematology-Oncology and Stem Cell Research, 15(3), 192-198. |
Chicago | Asiyabi S, Marashi SM, Vahabpour R, Nejati A, Azizisaraji A, Mustafa AS, Baghernejad A, Shoja Z, Mansouritorghabeh H. "Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group." International Journal of Hematology-Oncology and Stem Cell Research 15, no. 3 (2021): 192-198. |
Harvard | Asiyabi S et al. (2021) 'Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group', International Journal of Hematology-Oncology and Stem Cell Research, 15(3), pp. 192-198. |
Vancouver | Asiyabi S, Marashi SM, Vahabpour R, Nejati A, Azizisaraji A, Mustafa AS, et al.. Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group. International Journal of Hematology-Oncology and Stem Cell Research. 2021;15(3):192-198. |
BibTex | @article{ author = {Asiyabi S and Marashi SM and Vahabpour R and Nejati A and Azizisaraji A and Mustafa AS and Baghernejad A and Shoja Z and Mansouritorghabeh H}, title = {Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group}, journal = {International Journal of Hematology-Oncology and Stem Cell Research}, volume = {15}, number = {3}, pages = {192-198}, year = {2021} } |
RIS | TY - JOUR AU - Asiyabi S AU - Marashi SM AU - Vahabpour R AU - Nejati A AU - Azizisaraji A AU - Mustafa AS AU - Baghernejad A AU - Shoja Z AU - Mansouritorghabeh H TI - Parvovirus 4 in Individuals With Severe Hemophilia a and Matched Control Group JO - International Journal of Hematology-Oncology and Stem Cell Research VL - 15 IS - 3 SP - 192 EP - 198 PY - 2021 ER - |